{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:50:18Z","timestamp":1788277818348,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007301","name":"Harvard University Center for AIDS Research","doi-asserted-by":"publisher","award":["P30 AI060354"],"award-info":[{"award-number":["P30 AI060354"]}],"id":[{"id":"10.13039\/100007301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23 AI108293]"],"award-info":[{"award-number":["K23 AI108293]"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Cryptococcal antigen (CrAg) screening with fluconazole prophylaxis has been shown to prevent cryptococcal meningitis and mortality for people living with HIV (PLWH) with CD4\u2009&lt;\u2009100 cells\/mm<jats:sup>3<\/jats:sup>. While cryptococcal meningitis occurs in individuals with CD4 100\u2013200 cells\/mm<jats:sup>3<\/jats:sup>, there is limited evidence that CrAg screening predicts cryptococcal meningitis or mortality among this group with moderate immunosuppression. Current IDSA and WHO clinical guidelines recommend restricting CrAg screening to PLWH with CD4\u2009&lt;\u2009100 cells\/mm<jats:sup>3<\/jats:sup>.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a prospective cohort study of PLWH 18+ years who had not initiated ART in South Africa. We followed participants for 14\u2009months to determine onset of cryptococcal meningitis or all-cause mortality. At study completion, we retrospectively tested stored serum samples for CrAg using an enzyme immunoassay (EIA). We calculated CD4-stratified incidence rates of outcomes and used Cox proportional hazards to measure associations between CrAg positivity and outcomes.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We enrolled 2383 PLWH, and 1309 participants had serum samples tested by CrAg EIA. The median CD4 was 317 cells\/mm<jats:sup>3<\/jats:sup> (interquartile range: 173\u2013491 cells\/mm<jats:sup>3<\/jats:sup>). By CD4 count at baseline, there were 209 individuals with a CD4 count of 100\u2013200 cells\/mm<jats:sup>3<\/jats:sup> and available CrAg test results. Of these, four (1.9%) tested positive. Two of four (IR: 58.8 per 100 person-years) CrAg+ participants and 11 of 205 (IR: 5.6 per 100 person-years) CrAg- participants developed cryptococcal meningitis or died for an overall rate of death or cryptococcal meningitis that was 10.0-times higher for those who were CrAg+ (95% confidence interval: 2.2\u201345.3). Among those with CD4\u2009&lt;\u2009100 cell\/mm<jats:sup>3<\/jats:sup> and CrAg EIA test results (<jats:italic>N<\/jats:italic>\u2009=\u2009179), ten (5.6%) participants tested CrAg+. Among this group, seven of ten (IR: 137.6 per 100 person-years) CrAg+ participants and 26 of 169 (IR: 17.8 per 100 person-years) CrAg- participants developed cryptococcal meningitis or died, for a rate of death or cryptococcal meningitis that was 6.3-times higher for those who were CrAg+ (95% confidence interval: 2.7\u201314.6).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Although few PLWH with moderate immunosuppression screened CrAg positive, a positive CrAg test was predictive of increased risk of cryptococcal meningitis or death. Similar to those with a CD4\u2009&lt;\u2009100 cell\/mm<jats:sup>3<\/jats:sup>, systematic CrAg screening may reduce morbidity and mortality in PLWH with CD4 100\u2013200 cells\/mm<jats:sup>3<\/jats:sup>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-4798-1","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T16:02:38Z","timestamp":1579536158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100\u2013200 cells\/mm3"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-2742","authenticated-orcid":false,"given":"James","family":"Wykowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R.","family":"Galagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Govere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole L.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahomed-Yunus","family":"Moosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Celum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Drain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"key":"4798_CR1","unstructured":"Diagnosis THE, Cryptococcal MOF, Adults DINH. The Diagnosis, Prevention and Management of Cryptococcal Disease in Hiv-Infected Adults, Adolescents and Children Supplement To the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing Hiv Infection 2018."},{"issue":"12","key":"4798_CR2","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/cid\/ciw125","volume":"62","author":"J Stover","year":"2016","unstructured":"Stover J, Low A, Larke N, Drouin O, B-Lajoie M-R, Gavriilidis G, et al. Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in Low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(12):1595\u2013603.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4798_CR3","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/cid\/ciy567","volume":"68","author":"E Temfack","year":"2019","unstructured":"Temfack E, Bigna JJ, Luma HN, Spijker R, Meintjes G, Jarvis JN, et al. Impact of routine Cryptococcal antigen screening and targeted preemptive fluconazole therapy in antiretroviral-naive human immunodeficiency virus-infected adults with CD4 cell counts <100\/muL: a systematic review and meta-analysis. Clin Infect Dis. 2019 Feb;68(4):688\u201398.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4798_CR4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1365-3156.2007.01874.x","volume":"12","author":"CA Liechty","year":"2007","unstructured":"Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Tropical Med Int Health. 2007 Aug;12(8):929\u201335.","journal-title":"Tropical Med Int Health"},{"issue":"3","key":"4798_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/649858","volume":"50","author":"JR Perfect","year":"2010","unstructured":"Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010 Feb;50(3):291\u2013322.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4798_CR6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"Radha Rajasingham","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis [Internet]. 2017\/05\/05. 2017 Aug;17(8):873\u2013881. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28483415.","journal-title":"The Lancet Infectious Diseases"},{"issue":"Suppl 2","key":"4798_CR7","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1093\/cid\/cix1143","volume":"66","author":"N Ford","year":"2018","unstructured":"Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, et al. CD4 cell count threshold for Cryptococcal antigen screening of HIV-infected individuals: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(Suppl 2):S152\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4798_CR8","first-page":"1","volume":"10","author":"E Ndayishimiye","year":"2018","unstructured":"Ndayishimiye E, Ross AJ. An audit of the screen-and-treat intervention to reduce cryptococcal meningitis in HIV-positive patients with low CD4 count. African J Prim Heal Care Fam Med. 2018;10(1):1\u20137.","journal-title":"African J Prim Heal Care Fam Med"},{"issue":"6","key":"4798_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/infdis\/jiy602","volume":"219","author":"L Tugume","year":"2019","unstructured":"Tugume L, Rhein J, Hullsiek KH, Mpoza E, Kiggundu R, Ssebambulidde K, et al. HIV-associated Cryptococcal meningitis occurring at relatively higher CD4 counts. J Infect Dis. 2019 Feb;219(6):877\u201383.","journal-title":"J Infect Dis"},{"issue":"1","key":"4798_CR10","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1038\/s41598-018-37478-7","volume":"9","author":"PK Drain","year":"2019","unstructured":"Drain PK, Hong T, Krows M, Govere S, Thulare H, Wallis CL, et al. Validation of clinic-based cryptococcal antigen lateral flow assay screening in HIV-infected adults in South Africa. Sci Rep. 2019 Feb;9(1):2687.","journal-title":"Sci Rep"},{"issue":"1","key":"4798_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/sajhivmed.v18i1.776","volume":"18","author":"G Meintjes","year":"2017","unstructured":"Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, et al. Adult antiretroviral therapy guidelines 2017. S Afr J HIV Med. 2017;18(1):1\u201324.","journal-title":"S Afr J HIV Med"},{"issue":"1","key":"4798_CR12","doi-asserted-by":"publisher","first-page":"e0210105","DOI":"10.1371\/journal.pone.0210105","volume":"14","author":"R Rajasingham","year":"2019","unstructured":"Rajasingham R, Meya DB, Greene GS, Jordan A, Nakawuka M, Chiller TM, et al. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: a cost-effectiveness modeling analysis. PLoS One. 2019;14(1):e0210105.","journal-title":"PLoS One"},{"issue":"7","key":"4798_CR13","doi-asserted-by":"publisher","first-page":"e69288","DOI":"10.1371\/journal.pone.0069288","volume":"8","author":"JN Jarvis","year":"2013","unstructured":"Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, Cleary S. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One. 2013;8(7):e69288.","journal-title":"PLoS One"},{"key":"4798_CR14","unstructured":"Massyn N, Peer N, English R, Padarath A, Barron P, Day editors C. District health barometer 2015\/16. Durban Heal Syst Trust 2016;"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4798-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-4798-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4798-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:07:08Z","timestamp":1611014828000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-4798-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4798"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-4798-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"25 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All study participants provided written informed consent in English or Zulu. The study was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (BF052\/13) and the University of Washington Institutional Review Board (49563).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants\u2019 written consent for publication was obtained at the time of study enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}